Reducing the impact of novel SARS-CoV-2 variants is a critical focus of the global COVID-19 response. Genome Canada, through its leadership of the Canadian COVID Genomics Network (CanCOGeN), is part of an integrated national effort to rapidly identify, understand, and track the distribution of these variants in Canada.
(This statement is an updated version of our original statement of Dec. 22, 2020 when the first new variant was identified in the United Kingdom.)
$16 million in federal funding to support new genomics research in health, agriculture and the environment
As Canada addresses ongoing challenges posed by the COVID-19 pandemic and charts a course for economic recovery, harnessing the game-changing potential of genomics can deliver homegrown solutions and help protect and improve Canadian lives.
Drs. Elizabeth Douville (Chair of the Board of Directors) and Rob Annan (President and CEO) are pleased to announce the appointment of Dr. Bonnie Schmidt and Mr. Andrew Stephens to Genome Canada’s Board of Directors for two-year terms. Dr. Douville and existing Board members Mr. Eric Cook and Dr. Jacques Simoneau were reappointed for additional two-year terms.
Genome Canada is pleased to welcome Dr. Catalina Lopez-Correa as Executive Director, Canadian COVID Genomics Network (CanCOGeN), effective June 22, 2020.